Jade Mountain Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
Fastest customizable press release news feed in the world
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. (("Maxpro", NASDAQ:JMAC). Apollomics' Class A ordinary shares and public warrants are expected to commence trading today, March 30, 2023, on the Nasdaq Capital Market (Nasdaq) under the symbols "APLM" and "APLMW," respectively. The Business Combination, which was approved by Maxpro's shareholders on March 20, 2023,
Taipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company") announced today that its sponsor, MP One Investment LLC (the "Sponsor") and Apollomics Inc. ("Apollomics"), deposited additional payments in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the "Extension Payment") into the Company's trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from January 13, 2023 to April 13, 2023 (the "Extension"). The Extension is the second of two three-month extensions permitted under the Company
TAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company"), announced today that its sponsor, MP One Investment LLC (the "Sponsor"), has requested that the Company extend the date by which the Company has to consummate a business combination from January 13, 2023 to April 13, 2023 (the "Extension"). The Extension is the second of two three-month extensions permitted under the Company's governing documents. In connection with the Extension, the Sponsor and Apollomics Inc. ("Apollomics") have notified the Company that they intend to bear the cost of the Extension in the aggregate amount of $1,035,000 (representing $0.10 pe
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations. The FDA granted the Orphan Drug Designation in August. "While NSCLC is the most common type of lung cancer, a subset of patients will have MET genomic dysregulations in their tumors which make them more resistant to treatment, presenting an unmet medical need," sai
TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company") announced today that its sponsor, MP One Investment LLC (the "Sponsor"), deposited an additional payment in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the "Extension Payment") into the Company's trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from October 13, 2022 to January 13, 2023 (the "Extension"). The Extension is the first of two three-month extensions permitted under the Company's governing documents. The Exten
Taipei City, Oct. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company"), announced today that its sponsor, MP One Investment LLC (the "Sponsor"), has requested that the Company extend the date by which the Company has to consummate a business combination from October 13, 2022 to January 13, 2023 (the "Extension"). The Extension is the first of two three-month extensions permitted under the Company's governing documents. In connection with the Extension, the Sponsor has notified the Company that it intends to deposit an aggregate of $1,035,000 (representing $0.10 per public share) into the Company's trust account on or before October
– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs –Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined $11 billion non-small cell lung cancer ("NSCLC") and acute myeloid leukemia ("AML") market opportunity –Transaction proceeds to accelerate development of late-stage clinical programs, vebreltinib (APL-101) and uproleselan (APL-106) FOSTER CITY, Calif. and TAIPEI CITY, Taiwan, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company")
15-12G - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
10-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
25-NSE - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
425 - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
425 - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)